Levomil 40 Capsule ER contains Levomilnacipran 40 mg, an extended-release formulation indicated for the treatment of major depressive disorder (MDD). Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) that enhances neurotransmitter activity by inhibiting the reuptake of serotonin and norepinephrine, thereby improving mood and alleviating depressive symptoms. The extended-release capsule ensures a steady plasma concentration, promoting better tolerability and adherence through once-daily dosing. Clinical studies have demonstrated Levomilnacipran’s efficacy in reducing depressive symptoms, improving patient functioning, and enhancing quality of life. It is generally well-tolerated, with common adverse effects including nausea, headache, dry mouth, and increased heart rate. Caution is advised in patients with a history of cardiovascular disease, hypertension, or seizure disorders. Levomil 40 Capsule ER should be prescribed following a thorough clinical evaluation, considering potential drug interactions and contraindications such as concomitant use with monoamine oxidase inhibitors (MAOIs). Dose adjustments may be necessary in renal impairment. Patients should be monitored regularly for clinical response and emergent side effects, including suicidal ideation, particularly during the initial treatment phase or dosage changes. Levomil 40 Capsule ER offers an effective therapeutic option for managing major depressive disorder under appropriate medical supervision.